Cat Allergy (Immunology) Drugs In Development, 2021 Research Report Featuring ALK-Abello, Amgen, Angany, Regeneron Pharmaceuticals, Sementis & Worg Pharmaceuticals – | Business

Ad Blocker Detected

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.

DUBLIN – (BUSINESS WIRE) – Sept. August 2021–

The report “Cat Allergy (Immunology) – Drugs In Development, 2021” has been added to’s listing.

Cat Allergy – Drugs In Development, 2021, provides comprehensive information on the therapeutics in development for cat allergy (immunology), complete with analysis by development stage, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide includes the descriptive pharmacological effects of the therapeutic, its full research and development history, and the latest news and press releases.

The Pipeline Guide to Cat Allergy (Immunology) also provides an overview of the key stakeholders involved in the therapeutic development of cat allergy and includes dormant and discontinued projects. The guide covers therapeutics developed by companies / universities / institutes that are molecules developed by companies in Phase II, Preclinical and Discovery phase 2, 2 and 2 respectively.

The Cat Allergy (Immunology) Pipeline Guide will help identify and track emerging players in the market and their portfolios, improve decision-making skills, and help develop effective counter-strategies to gain competitive advantage.

Reasons to buy

  • Acquire strategically important competitive intelligence, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and develop effective counter-strategies to achieve competitive advantages.
  • Find and recognize major and diverse types of therapeutics in development for cat allergy (immunology).
  • Classify potential new customers or partners in the target group.
  • Develop tactical initiatives by understanding the priorities of leading companies.
  • Make sense of mergers and acquisitions by identifying key players and the most promising therapeutics in the pipeline.
  • Formulate corrective actions for pipeline projects by understanding the depth of the cat allergy (immunology) pipeline and the focus of indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying potential partners with the most attractive projects to improve and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them out of the pipeline.

Key topics covered:


Cat Allergy Overview

  • Cat Allergy – Therapeutic Development

Pipeline overview

  • Pipeline by company
  • Products in enterprise development

Cat Allergy – Therapeutic Evaluation

  • Assessment by goal
  • Evaluation according to the mechanism of action
  • Assessment by route of administration
  • Assessment by type of molecule

Cat Allergy – Companies Involved in Therapeutic Development

  • ALK-Abello AS
  • Amgen Inc
  • Angany Inc
  • Regeneron Pharmaceuticals Inc
  • Plants Ltd.
  • Worg Pharmaceuticals Hangzhou Co Ltd

Cat Allergy – Medication Profiles

  • Allergen for Cat Allergy – Active Ingredient Profile
  • Product description
  • Mechanism of action
  • R&D progress
  • REGN-19081909 – Drug Profile
  • Tezepelumab – active ingredient profile
  • Cat Allergy Vaccine – Active Ingredient Profile
  • WP-1075 – Drug Profile
  • R&D progress

Cat Allergy – Dormant Projects

Cat Allergy – Discontinued Products


Mentioned companies

  • ALK-Abello AS
  • Amgen Inc
  • Angany Inc
  • Regeneron Pharmaceuticals Inc
  • Plants Ltd.
  • Worg Pharmaceuticals Hangzhou Co Ltd

Please visit for more information on this report

View source version on https: //


Laura Wood, Senior Press Manager

For EST office hours, call 1-917-300-0470

For US / CAN toll free call 1-800-526-8630

For GMT office hours, call + 353-1-416-8900. on



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 08/19/2021 10:32 a.m. / DISC: 08/19/2021 10:32 a.m.

Copyright Business Wire 2021.